Skip to main content
Retour
RGC logo

Regencell Bioscience Holdings Limited

Qualité des données : 100%
RGC
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
25,22 €
▼ 2,16 € (-7,87%)
Cap. Boursière : 12,47B
Fourchette du Jour
24,86 € 27,02 €
Fourchette 52 Semaines
0,55 € 83,60 €
Volume
112 793
Moyenne 50J / 200J
28,38 € / 20,03 €
Clôture Précédente
27,37 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -3478,7 0,4
P/B 2565,4 2,9
ROE % -54,8 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Aucune estimation prévisionnelle disponible

Points Clés

Debt/Equity of 0,11 — conservative balance sheet
Negative free cash flow of -3,27M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-54,81%
ROIC-52,32%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,11
Current Ratio7,39
Interest Coverage0,00

Valorisation

P/E Ratio
-3478,74
P/B Ratio2565,40
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -3,58M
ROE -54,81% ROA -62,27%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,27M
ROIC -52,32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,11 Current Ratio 7,39
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -3478,74 P/B Ratio 2565,40
P/S Ratio N/A PEG Ratio 136,35
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 12,47B Enterprise Value 12,47B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -3,58M -4,30M -5,87M -7,42M -1,35M
EPS (Diluted) -0,01 -0,01 -0,01 -0,02 0,00
Gross Profit -392 743,0 -745 588,0 -769 687,0 -604 397,0 -26 456,0
Operating Income -3,77M -4,74M -6,27M -7,62M -1,38M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5,76M 8,44M 12,62M 18,02M 340 134,0
Total Liabilities 895 308,0 219 512,0 632 320,0 938 032,0 4,34M
Shareholders' Equity 4,86M 8,22M 12,03M 17,07M -4,00M
Total Debt 544 415,0 85 741,0 463 669,0 771 255,0 3,68M
Cash & Equivalents 2,42M 2,96M 1,56M 6,42M 59 413,0
Current Assets 4,90M 8,11M 11,62M 16,44M 66 849,0
Current Liabilities 663 673,0 193 578,0 606 914,0 577 764,0 4,34M